Skip to main content
EJNMMI Research
Fig. 3 | EJNMMI Research

Fig. 3

From: A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial

Fig. 3

Two 68Ga-satoreotide trizoxetan PET/CT fused images with maximum intensity projection of the same patient acquired at two different timepoints separated by 2–3 weeks. In the top panel, the patient had received 68Ga-satoreotide trizoxetan at 16 µg/165 MBq. In the lower panel, the patient had received 68Ga-satoreotide trizoxetan at 32 µg/72 MBq. Abbreviations: CT, computed tomography; PET, positron emission tomography

Back to article page